title: [Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer].
abstract: TIN (ifosfamide 1.5 g/m2 daily for 3 days, paclitaxel 175 mg/m2, and nedaplatin 70 mg/m2 on day 1) was administered to patients with metastatic urothelial cancer previously treated by platinum-based chemotherapy and repeated every 4 weeks. Four patients received maintenance therapy, which consisted of 5'-DFUR 800 mg/day orally for 12 weeks and 1 subsequent course of TIN. This therapy regimen was repeated for 2 years from initiation of TIN. Eleven of 12 patients (91.6%) demonstrated a major response (3 complete responses, 8 partial responses), with durations of response ranging from 3 to 20 months. Progression-free survival time was from 0 to 20 months (median 8 months). One-year progression-free survival rate was 45.8%. Overall survival time was from 2 to 20 months (median 10.5 months). One-year overall survival rate was 53.5%. Grade 3/4 hematologic toxicity involved neutropenia in 100% and thrombocytopenia in 33.3%. Febrile neutropenia was observed in 5 patients (41.6%). Grade 3 nonhematologic toxicity involved malaise in 15.3%. No patient discontinued this therapy because of complications. TIN is a potent, well-tolerated regimen for previously treated patients with urothelial cancer.
authors.affiliation: Dept. of Urology, Graduate School of Medicine, Hokkaido University.
authors.forename: Shin
authors.initials: S
authors.lastname: Suzuki
authors.forename: Nobuo
authors.initials: N
authors.lastname: Shinohara
authors.forename: Toru
authors.initials: T
authors.lastname: Harabayashi
authors.forename: Haruo
authors.initials: H
authors.lastname: Seki
authors.forename: Masashi
authors.initials: M
authors.lastname: Murakumo
authors.forename: Ryuta
authors.initials: R
authors.lastname: Ishikawa
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Demura
authors.forename: Kimiyoshi
authors.initials: K
authors.lastname: Mitsuhashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Toyota
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Koyanagi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D009944:Organoplatinum Compounds; C053989:nedaplatin; D017239:Paclitaxel; D007069:Ifosfamide